Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Nurix Therapeutics, Inc. (NRIX) has a Wall Street consensus price target of $31.22, based on estimates from 17 covering analysts. With the stock currently trading at $15.97, this represents a potential upside of +95.5%. The company has a market capitalization of $1.63B.
Analyst price targets range from a low of $28.00 to a high of $36.00, representing a 26% spread in expectations. The median target of $30.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NRIX trades at a trailing P/E of -5.2x. Analysts expect EPS to grow -12.4% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how NRIX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for NRIX is $31.22, representing 95.5% upside from the current price of $15.97. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NRIX has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $31.22 implies 95.5% upside from current levels.
NRIX's current price is $15.97 with a consensus target of $31.22 (95.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $36 for NRIX, while the most conservative target is $28. The consensus of $31.22 represents the median expectation. These targets typically reflect 12-month expectations.
NRIX is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NRIX stock forecast based on 17 Wall Street analysts shows a consensus price target of $31.22, with estimates ranging from $28 (bear case) to $36 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NRIX, with a "Buy" consensus rating and $31.22 price target (95.5% upside). 17 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NRIX analyst price targets range from $28 to $36, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31.22 consensus represents the middle ground.